NeuroSense Secures Japanese Patent for PrimeC ALS Treatment Through 2042
Event summary
- NeuroSense Therapeutics received a Japanese patent (7857044) for PrimeC's ALS treatment composition, valid through 2042.
- The patent covers 17 claims related to PrimeC's unique formulation and synchronized delivery of ciprofloxacin and celecoxib.
- PrimeC has shown clinical and biomarker benefits in Phase 2b PARADIGM study, including significant survival benefits.
- NeuroSense is preparing for a Phase 3 pivotal study (PARAGON) in ALS, expected to enroll 300 participants primarily in the U.S.
The big picture
NeuroSense's Japanese patent grant strengthens its global IP estate for PrimeC, a critical asset as it advances toward a pivotal Phase 3 trial in ALS. The patent underscores the company's strategy to target multiple disease mechanisms, positioning PrimeC as a potential breakthrough in a market with limited treatment options. The ALS market, with an annual disease burden of $1 billion in the U.S. alone, represents a significant opportunity for NeuroSense if PrimeC's clinical benefits are confirmed in larger studies.
What we're watching
- Regulatory Progress
- How the Japanese patent will support NeuroSense's long-term commercialization strategy in a key pharmaceutical market.
- Clinical Trial Execution
- Whether the Phase 3 PARAGON study will confirm PrimeC's clinical and survival benefits observed in earlier trials.
- Market Expansion
- The pace at which NeuroSense can leverage its global IP portfolio to enter additional strategic markets.
Related topics